Stock Analysis on Net
Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Common-Size Income Statement
Quarterly Data

Abiomed Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016
Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of revenue -18.38 -18.99 -19.07 -18.24 -17.69 -17.89 -19.10 -17.75 -18.47 -21.83 -19.05 -18.05 -17.01 -17.85 -16.83 -16.96 -16.42 -17.14 -17.25 -16.23 -16.28 -16.50 -15.45 -16.56 -16.81 -14.63
Gross profit 81.62% 81.01% 80.93% 81.76% 82.31% 82.11% 80.90% 82.25% 81.53% 78.17% 80.95% 81.95% 82.99% 82.15% 83.17% 83.04% 83.58% 82.86% 82.75% 83.77% 83.72% 83.50% 84.55% 83.44% 83.19% 85.37%
Research and development -15.83 -14.60 -16.23 -15.65 -16.54 -14.93 -13.26 -14.25 -14.55 -15.99 -12.26 -11.58 -11.69 -11.46 -12.34 -11.95 -12.50 -11.82 -12.19 -11.50 -14.60 -12.78 -13.09 -14.26 -17.53 -15.20
Selling, general and administrative -43.98 -42.57 -40.62 -41.21 -41.42 -40.97 -41.61 -37.21 -37.74 -41.52 -40.59 -38.66 -41.94 -41.45 -39.26 -40.00 -43.40 -45.07 -43.28 -43.21 -45.23 -45.74 -48.20 -47.03 -51.56 -49.55
Acquired in-process research and development 0.00 0.00 0.00 -0.19 0.00 -45.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income (loss) from operations 21.81% 23.83% 24.09% 24.72% 24.36% -19.51% 26.03% 30.80% 29.24% 20.66% 28.09% 31.71% 29.36% 29.24% 31.58% 31.09% 27.68% 25.97% 27.27% 29.06% 23.89% 24.97% 23.25% 22.15% 14.09% 20.62%
Interest and other income (expense), net 30.35 1.36 3.62 -2.56 2.75 15.81 4.43 4.05 5.52 16.38 -9.07 12.08 -20.89 20.42 16.00 1.07 0.83 0.97 0.54 0.58 0.57 0.54 0.29 0.37 0.22 0.19
Income (loss) before income taxes 52.16% 25.19% 27.71% 22.16% 27.11% -3.70% 30.46% 34.85% 34.76% 37.05% 19.02% 43.78% 8.47% 49.67% 47.58% 32.16% 28.51% 26.94% 27.81% 29.64% 24.46% 25.51% 23.55% 22.52% 14.31% 20.80%
Income tax (provision) benefit -12.25 -5.51 -5.35 -4.64 -4.16 -6.80 -6.90 -8.14 -5.10 -10.00 -3.64 -12.55 -2.09 -6.85 -11.86 -9.80 -0.94 23.10 -6.68 -20.91 -6.01 2.70 -11.60 -9.06 -5.69 -8.27
Net income (loss) 39.91% 19.68% 22.36% 17.52% 22.95% -10.50% 23.57% 26.71% 29.66% 27.05% 15.39% 31.24% 6.38% 42.82% 35.72% 22.37% 27.58% 50.03% 21.12% 8.73% 18.45% 28.21% 11.95% 13.46% 8.62% 12.53%

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).

Income statement item Description The company
Income (loss) from operations The net result for the period of deducting operating expenses from operating revenues. Abiomed Inc. income (loss) from operations as a percentage of revenue decreased from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023.
Income (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Abiomed Inc. income (loss) before income taxes as a percentage of revenue decreased from Q4 2022 to Q1 2023 but then increased from Q1 2023 to Q2 2023 exceeding Q4 2022 level.
Net income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Abiomed Inc. net income (loss) as a percentage of revenue decreased from Q4 2022 to Q1 2023 but then increased from Q1 2023 to Q2 2023 exceeding Q4 2022 level.